Key Companies Covered in the ‘Global Chemotherapy Market’ Research Report by Kenneth Research are Amgen Inc., Pfizer Inc., ALMATICA PHARMA LLC., Bayer AG, Puma Biotechnology, Inc., Sanofi, Astellas Pharma Inc., CLOVIS ONCOLOGY, Novartis AG, BeiGene, Ltd., and other key market players.
New York, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Kenneth Research has published a detailed market report on ‘Global Chemotherapy Market’ for the forecast period, i.e. 2022 – 2031, which includes the following factors:
Market growth over the forecast period
Profiling of key market players
The global chemotherapy market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022–2031. Moreover, in the year 2021, the market registered a remarkable revenue. The growth of the market can be attributed to the rising cancer cases and the increasing population. For instance, according to a report by the World Health Organisation, worldwide, the second leading reason for mortality is cancer that, accounted for approximately 9.6 million deaths in 2018. Additionally, the increase in the expenditure on medicine and research and development are some of the major factors expected to boost the growth of the global chemotherapy market. Moreover, increasing health expenditure across the globe, rising patient population across the world and advancement in healthcare infrastructure, and growing governmental initiatives and campaigns to spread awareness regarding cancer and its treatment are predicted to drive market growth over the ensuing years.
Get a Sample PDF of This Report @ https://www.kennethresearch.com/sample-request-10094818
Global Chemotherapy Market: Key Takeaways
The Asia Pacific region gains the largest portion of the revenue
The breast cancer segment to dominate the revenue graph
Female segment remains prominent in the system segment
Increasing Geriatric Population to Boost Market Growth
The rise in geriatric population all over the world, and increasing incidences of chronic diseases, are responsible for the market's development over the forecast period. It was noticed the number and proportion of geriatric population, meaning the people aged 60 years and older in the population was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, better provision for reimbursement policies in advanced economies is also estimated to add in the growth of the market. Besides, growing patient population across the world and advancement in healthcare infrastructure are projected to majorly drive the market growth.
In addition to this, increasing cases of cancer across the globe is estimated to be a prime factor to add to the market growth. According to the World Health Organization, nearly 10 million people died of cancer across the globe in 2020. The most recurrent cases of deaths because of cancer were lung cancer which caused 1.80 million deaths, colon and rectum cancer which caused 916 000 deaths, liver cancer which caused 830 000 deaths, stomach cancer which caused 769 000 deaths, and breast cancer which caused 685 000 deaths. Furthermore, it was noticed that about 30% of cancer cases in low and lower-middle income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis. Moreover, the rising investments in the R&D activities to continuously bring up more feasible solutions for medical procedures along with launch of new products are predicted to propel the global chemotherapy market over the forecast period.
Browse to access In-depth research report on Global Chemotherapy Market with detailed charts and figures: https://www.kennethresearch.com/report-details/chemotherapy-market/10094818
Global Chemotherapy Market: Regional Overview
The global chemotherapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region.
Rapidly Increasing Population Expected to Boost Market Growth in the Asia Pacific Region
The Asia Pacific region in the global chemotherapy market is estimated to witness modest growth over the forecast period on the back of a rising population in the particular region. According to the World Bank, China and India are among the countries with the largest population, having 1.41 and 1.39 billion population respectively, in 2021, and their numbers are increasing on a yearly basis. Additionally, the rising cancer awareness among the population and increasing expenditure on research related to cancer in this region are further expected to boost the market growth. Moreover, the role of government in spreading awareness about the chemotherapy are expected to boost the growth of the chemotherapy market in this region.
Get a Sample PDF of Chemotherapy Market @ https://www.kennethresearch.com/report-details/chemotherapy-market/10094818
Increasing Cancer Cases to Favor Market Growth in the North America Region
The North America region is estimated to witness a substantial growth in the year of 2021. This growth can be accredited to the availability of advance technologies, and well-established healthcare facilities. Additionally, increasing disposable income per capita among the regional population is also expected to be an important factor to boost the growth of the market in the region. According to the data by the World Bank, in 2020 disposable income per capita in the North America region was USD 51,407. Hence, this is expected to be a prime factor to fuel the growth of chemotherapy market in the region. Moreover, high prevalence of cancer all over the region is anticipated to be another major factor to drive the regional market. It was noted that, about 2 million new cancer cases and more than 690,000 cancer deaths occurred in Northern America in 2018.
The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in:
North America (U.S., Canada)
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe)
Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific)
Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.kennethresearch.com/sample-request-10094818
Global Chemotherapy Market, Segmentation by Cancer Type
The breast cancer segment in the global chemotherapy market is estimated to witness the highest growth over the forecast period. The growth of the segment can be attributed to the increasing awareness among people related to breast cancer. According to the World Cancer Research Fund, 2,261,419 new breast cancer cases were reported in the year 2020, which constitutes the highest number in relation to other cancer types. Therefore, rising breast cancer cases are expected to increase the growth of the global chemotherapy market. Global Chemotherapy Market, Segmentation by Gender Type
The female segment is estimated to hold a substantial market share in the global chemotherapy market during the forecast period. The segmental growth can be ascribed to the prevalence of breast cancer throughout the world and growing female population. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most prevalent cancer.
Global Chemotherapy Market, Segmentation by Product Type
Few of the well-known market leaders in the global chemotherapy market that are profiled by Kenneth Research are Amgen Inc., Pfizer Inc., ALMATICA PHARMA LLC., Bayer AG, Puma Biotechnology, Inc., Sanofi, Astellas Pharma Inc., CLOVIS ONCOLOGY, Novartis AG, BeiGene, Ltd., and others.
For More Information or Query or Required Customization @ https://www.kennethresearch.com/report-details/chemotherapy-market/10094818
Recent Developments in the Global Chemotherapy Market
In January 2022, Tislelizumab, produced by BeiGene, Ltd., was authorised by the China National Medical Products Administration (NMPA) as a second or third line treatment for people with locally advanced or metastatic non-small cell lung cancer.
In January 2021, Food and Drug Administration (FDA) gave Pfizer's XALKORI approval for use in treating ALK-positive anaplastic large cell lymphoma in adolescents and young adults.
Preclinical CRO Market Segmentation by End-User (Biopharmaceutical Industries, Medical Device Companies, and Academic Institutes & Government); and by Service (Bioanalysis & DMPK Studies, Toxicology Testing, Compound Management, Chemistry, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Cannabidiol (CBD) Market Analysis by Source (Marijuana, and Hemp); by Product (Oil, Tinctures, and Others); by Distribution Channel (Online and Offline), by Application (Anxiety/stress, Sleep/insomnia, and Others), and by Route of Administration (Oral, Topical, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031
Antihypertensive Drugs Market Analysis by Drug Class (Calcium Channel Blockers, ACE Inhibitors, Adrenergic Blockers, Angiotensin II Receptor Blockers, Diuretics, Vasodilators, and Others); and by Distribution Channel (Hospital, Retail, and Online Pharmacy)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031
Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Web: https://www.kennethresearch.com/
Immunocore Holdings plc (NASDAQ: IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well tolerated and resulted in durable responses across multiple solid tumor types. Fifty-five patients have been treated across ten dose cohorts. IMC-F106C was well-tolerated, with treatment-related adverse events that were manageable and consistent with the mechanism of action. In the clinically active dose cohorts, durable partial responses (
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
Shares of Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) climbed 160.4% this week, according to data from S&P Global Intelligence. The stock closed at $14.90 last Friday and then opened this Tuesday at $12.16. The stock began trading on Aug. 31 after its initial public offering (IPO).
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.
These strategies can help you reduce your health care costs.
Parkinson's disease (PD) may be an issue that stems from the health and function of your brain, according to the National Institute on Aging. However, a new study recently published by JAMA Network Open also reveals a connection between eating habits and mortality rates for those with PD.In a study titled "Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease," researchers took a look at 1,251 participants who were previously diagnosed with Parkin
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.
Cara Therapeutics Inc (NASDAQ: CARA) announced results from the KOMFORT Phase 2 clinical trial of oral difelikefalin for moderate-to-severe pruritus in notalgia paresthetica (NP). Notalgia paresthetica (NP) is a nerve disorder that causes intense and sometimes painful itching in the back impacting quality of life. The data will be presented at the European Academy of Dermatology and Venereology (EADV) Congress. The presentation includes data from 125 patients with NP and moderate-to-severe pruri
ALBANY, N.Y. — New York declared a state of emergency on Friday to boost vaccinations against polio. Gov. Kathy Hochul issued an executive order expanding the state’s network of vaccine administrators to EMS workers, midwives and pharmacists as evidence mounts that the once rare virus is spreading in the state. Only one case of paralytic polio has been recorded in Rockland County so far, but ...
CLAIM: A federal court order in the legal dispute over government documents held by former President Donald Trump shows President Joe Biden ordered the FBI search at Trump’s Florida home. THE FACTS: While Monday's court order from U.S. District Judge Aileen Cannon does include the phrase “as requested by the incumbent president” it’s not related to last month’s search at Mar-a-Lago. The phrase comes from a May letter from the National Archives denying Trump’s request to delay turning over documents to the FBI.
For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .
The updated omicron-specific COVID-19 booster is important to get right away, a doctor says.
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
It seems like every major technology company wants to disrupt healthcare. It's easy to see why as the United States spends nearly 18% of its gross domestic product (GDP) on healthcare. "...Because national health expenditures are projected to grow 1.1 percentage points faster than gross domestic product per year on average over 2019-28, the health share of the economy is projected to rise from 17.7% in 2018 to 19.7% in 2028."
Scott Taylor never got to move on from COVID-19. The analysis was based on data from 20 major U.S. hospital systems, including more than 1.3 million adults with a COVID diagnosis and 19,000 with a long COVID diagnosis between May 2020 and July 2022.
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the KRYSTAL-1 Phase 1/2 study of adagrasib with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2022. In this analysis, 44 patients received adagrasib monotherapy, and 32 received the combination of adagrasib + cetuximab, with a follow-up of 20.1 months and 17.5 months, respectively. Related: Mi
His daughter said the hospital saved her father's life.